← Back to patent-cliff list
ENX-102
Tier C — Watch / tradeENX-102
Engrail Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GABAAR
Indications (approved)：Anxiety, Anxiety disorder
Regional status
US
Phase II
2023-07-03
EU
Phase II
2024-12-09
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ENX-102?
Approved indications include: Anxiety, Anxiety disorder.
When does the ENX-102 patent expire?
No public expiry year is available for ENX-102 yet; this page updates once verified.
How do I get a quote for ENX-102 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02